About Viatris
Frequently Asked Questions
Q: What is Viatris?
A: Viatris is a new company that is the combination of Mylan and Upjohn, a legacy division of Pfizer.
A: Viatris is a new company that is the combination of Mylan and Upjohn, a legacy division of Pfizer.
Q: Which products from Upjohn, a legacy division of Pfizer, will be included in the transition to Viatris?
A: The following products will be included in the transition to Viatris:
A: The following products will be included in the transition to Viatris:
- CADUET®(amlodipine besylate/atorvastatin calcium) tablets
- CARDURA®(doxazosin mesylate) tablets
- CARDURA® XL (doxazosin mesylate extended
- CELEBREX®(celecoxib) capsules
- DETROL®(tolterodine tartrate) tablets
- DETROL® LA(tolterodine tartrate) extended-release capsules
- DILANTIN®(extended phenytoin sodium) capsules
- EFFEXOR XR®(venlafaxine HCl) extended-release capsules
- GEODON®(ziprasidone HCl)
- INSPRA®(eplerenone) tablets
- LIPITOR®(atorvastatin calcium) tablets
- LYRICA®(pregabalin) Capsules CV
- LYRICA® CR(pregabalin) extended-release tablets
- NEURONTIN®(gabapentin)
- NITROSTAT®(nitroglycerin) sublingual tablet
- NORVASC®(amlodipine besylate) tablets
- RELPAX®(eletriptan hydrobromide) tablets
- REVATIO®(sildenafil) oral suspension
- REVATIO®(sildenafil) tablets
- SERMION®(nicergoline) tablets
- VIAGRA®(sildenafil citrate) tablets
- XALATAN®(latanoprost ophthalmic solution) 0.005%
- XANAX® CIV (alprazolam) tablets)
- ZOLOFT®(sertraline hydrochloride)
Q: How long will Pfizer manage the Patient Assistance Program for legacy Upjohn products?
A: Pfizer will continue to manage the Patient Assistance Program for certain Upjohn products for a period of 12 months from November 16th, 2020
A: Pfizer will continue to manage the Patient Assistance Program for certain Upjohn products for a period of 12 months from November 16th, 2020
Q: How will this transition impact patient access to medicines?
A: There will be no impact to patients eligible for, or currently participating in, the Pfizer Patient Assistance Program.
A: There will be no impact to patients eligible for, or currently participating in, the Pfizer Patient Assistance Program.
Q: Will there be any impact to my current enrollment for these medicines?
A: There will be no impact to a patient’s current enrollment in the Pfizer Patient Assistance Program for these medications.
A: There will be no impact to a patient’s current enrollment in the Pfizer Patient Assistance Program for these medications.
Q: I receive other Pfizer medicines, will there be changes there too?
A: There will be no changes to how patients access their other Pfizer medicines.
A: There will be no changes to how patients access their other Pfizer medicines.
Q: Where can I go for more information about Viatris?
A: For more information about Viatris, please visit their website at www.Viatris.com or call 1-724-514-1800.
A: For more information about Viatris, please visit their website at www.Viatris.com or call 1-724-514-1800.